PDF(Pubmed)
Abstract：
UNASSIGNED: Disease modifying therapies (DMTs) used to treat multiple sclerosis (MS) can be associated to the occurrence of hematological disorders. This systematic review aims to provide an overview of these events occurring in real-life conditions, by describing case reports and series published in the literature.
UNASSIGNED: A literature search of all publications up to January 5th 2024 on the Medline and Embase databases was carried out. The results were presented both in the text and in tables.
UNASSIGNED: Sixty-seven case reports/series were included in this review, of which more than half related to alemtuzumab, natalizumab and ocrelizumab. The publication date of included studies ranged from 2006 to 2024. The majority of case reports and series described the occurrence of late-onset hematological disorders (events that occurred more than 30 days after the first DMT administration), mainly represented by case of neutropenia, autoimmune hemolytic anemia and immune thrombocytopenia. All cases reported a favorable outcome, apart one case report that described a fatal case. Among included cases, 4 articles, all related to natalizumab, described the occurrence of myeloid disorders in 13 newborns from mother receiving the DMT.
UNASSIGNED: Considering the limitations identified in the majority of included studies, further ad hoc studies are strongly needed to better evaluate the hematological disorders of DMTs. Meantime, the strict monitoring of treated patients for the occurrence of these toxicities should be highly recommended.
UNASSIGNED: A literature search of all publications up to January 5th 2024 on the Medline and Embase databases was carried out. The results were presented both in the text and in tables.
UNASSIGNED: Sixty-seven case reports/series were included in this review, of which more than half related to alemtuzumab, natalizumab and ocrelizumab. The publication date of included studies ranged from 2006 to 2024. The majority of case reports and series described the occurrence of late-onset hematological disorders (events that occurred more than 30 days after the first DMT administration), mainly represented by case of neutropenia, autoimmune hemolytic anemia and immune thrombocytopenia. All cases reported a favorable outcome, apart one case report that described a fatal case. Among included cases, 4 articles, all related to natalizumab, described the occurrence of myeloid disorders in 13 newborns from mother receiving the DMT.
UNASSIGNED: Considering the limitations identified in the majority of included studies, further ad hoc studies are strongly needed to better evaluate the hematological disorders of DMTs. Meantime, the strict monitoring of treated patients for the occurrence of these toxicities should be highly recommended.
摘要：
用于治疗多发性硬化(MS)的疾病改善疗法(DMT)可与血液学病症的发生有关。本系统综述旨在概述这些事件在现实生活中发生的情况，通过描述文献中发表的病例报告和系列。
■在Medline和Embase数据库上对截至2024年1月5日的所有出版物进行了文献检索。结果在文本和表格中呈现。
■本综述包括67例病例报告/系列，其中一半以上与阿仑单抗有关，那他珠单抗和奥克瑞珠单抗。纳入研究的发表日期为2006年至2024年。大多数病例报告和系列描述了迟发性血液病的发生（首次DMT给药后30天以上发生的事件），主要表现为中性粒细胞减少症，自身免疫性溶血性贫血和免疫性血小板减少症。所有病例都报告了有利的结果，除了一个病例报告描述了一个致命的病例。在包括的案件中，4条,都和那他珠单抗有关,描述了接受DMT的母亲的13名新生儿的骨髓性疾病的发生。
■考虑到大多数纳入研究的局限性，需要进一步的研究来更好地评估DMT的血液系统疾病.同时,强烈建议对接受治疗的患者严格监测这些毒性的发生。
■在Medline和Embase数据库上对截至2024年1月5日的所有出版物进行了文献检索。结果在文本和表格中呈现。
■本综述包括67例病例报告/系列，其中一半以上与阿仑单抗有关，那他珠单抗和奥克瑞珠单抗。纳入研究的发表日期为2006年至2024年。大多数病例报告和系列描述了迟发性血液病的发生（首次DMT给药后30天以上发生的事件），主要表现为中性粒细胞减少症，自身免疫性溶血性贫血和免疫性血小板减少症。所有病例都报告了有利的结果，除了一个病例报告描述了一个致命的病例。在包括的案件中，4条,都和那他珠单抗有关,描述了接受DMT的母亲的13名新生儿的骨髓性疾病的发生。
■考虑到大多数纳入研究的局限性，需要进一步的研究来更好地评估DMT的血液系统疾病.同时,强烈建议对接受治疗的患者严格监测这些毒性的发生。
